Collegium Pharmaceutical's (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
The company's full-year revenue guidance of $815 million at the midpoint came in 1% above analysts' estimates. Its non-GAAP profit of $2.04 per share was 4.7% below analysts' consensus estimates. Is now the time to buy Collegium Pharmaceutical? Find out in our full research report Collegium Pharmaceutical (COLL) Q4 CY2025 Highlights: Revenue: $205.4 million vs analyst estimates of $206.4 million (12.9% year-on-year growth, in line) Adjusted EPS: $2.04 vs analyst expectations of $2.14 (4.7% miss) Adjusted EBITDA: $127.3 million vs analyst estimates of $126.2 million (62% margin, 0.9% beat) EBITDA guidance for the upcoming financial year 2026 is $465 million at the midpoint, above analyst estimates of $451.1 million Operating Margin: 29.6%, up from 20.9% in the same quarter last year Market Capitalization: $1.45 billion “In 2025, we delivered on our strategic priorities by driving significant growth for Jornay PM, maximizing the durability of our pain portfolio, and st
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical (COLL) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "buy (b-)" to "hold (c+)".MarketBeat
- Collegium to Present New Real-World Data at PainConnect 2026GlobeNewswire
- Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community [Yahoo! Finance]Yahoo! Finance
- Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD CommunityGlobeNewswire
- Collegium to Participate in Upcoming Investor ConferencesGlobeNewswire
COLL
Earnings
- 2/26/26 - Beat
COLL
Sec Filings
- 3/5/26 - Form 4
- 3/3/26 - Form 144
- 2/26/26 - Form 10-K
- COLL's page on the SEC website